Clinical trials: Hematologic
Multiple Myeloma
Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients
1. Description of the demographic, clinical, and laboratory characteristics of patients with MM admitted to the hematology unit of Assuit University Hospitals. 2.
- Trial name
- NCT06457464
- Testing
- Chemotherapy
- Volunteers
- 100 people
- Sponsor
- Assiut University
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Aim of this prospective randomized trial is to compare maintenance treatment with panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach of pre-emptive DLI alone in patients with poor-risk…
- Trial name
- NCT04326764
- Testing
- Panobinostat
- Where
- 19 sites in Germany, Netherlands
- Volunteers
- 52 people
- Sponsor
- Goethe University
Snake Bite, Blood Coagulation Disorders
A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,
This phase II study was a prospective, randomized, open-label, multi-center study in the United States, involving patients from 18 to 70 years of age, comparing Anavip (Antivenin Crotalinae [pit viper] equine immune F(ab)2…
- Trial name
- NCT00868309
- Testing
- Anavip, CroFab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Multiple Myeloma
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
This clinical trial evaluates the impact of a plant-based whole-foods delivery service on the microbiome in patients with multiple myeloma undergoing an autologous hematopoietic cell transplant.
- Trial name
- NCT06559709
- Testing
- Biospecimen Collection, Dietary Intervention, Medical Chart Review
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Fred Hutchinson Cancer Center
Essential Thrombocythemia, Myelofibrosis
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm.
- Conditions
- Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera
- Trial name
- NCT03878199
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Multiple Myeloma (MM)
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM).
- Trial name
- NCT07746232
- Testing
- DW-MRI (MY-RADS/RAC score), Fat Fraction (rFF%), Clinical Data Collection
- Where
- 10 sites in Italy
- Volunteers
- 92 people
- Sponsor
- Fondazione EMN Italy Onlus
Hematological Malignancy, Neutropenia
Effect of Body Mass on Filgrastim Pharmacokinetics
Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher…
- Trial name
- NCT01719432
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aaron Cumpston, PharmD, BCOP
Chronic Myeloid Leukemia
Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase
This study is a multicenter observational study aimed to investigate the efficacy and safety of olverembatinib dose reduction to 20 mg every other day (QOD) in patients with chronic myeloid leukemia (CML) in chronic phase or…
- Trial name
- NCT07383298
- Testing
- Olverembatinib 20mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qian Jiang
Myelofibrosis (MF)
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue.
- Trial name
- TRANSFORM-1 (NCT04472598)
- Testing
- Ruxolitinib, Navitoclax
- Where
- 194 sites in United States, Australia and 23 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Acute Lymphoblastic Leukemia, Philadelphia Chromosome
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
ABC study is a phase 2, single-arm, open-label study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in patients with newly diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL
- Trial name
- ABC (NCT06220487)
- Testing
- Prednisone, Olverembatinib, Blinatumomab, Chidamide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Sickle Cell Disease
SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge
The purpose of this study is to test a web-aided, mobile-based PHR (Personal Health Reporting) service to enhance SCD outpatient treatment after discharge from an acute care setting, such as Duke University Medical Center's Day…
- Trial name
- NCT02475993
- Testing
- SMART app
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Sickle Cell Disease, Sickle Cell Nephropathy
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2)…
- Trial name
- NCT04335721
- Testing
- Voxelotor
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Multiple Myeloma, New Diagnosis Tumor
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
- Trial name
- NCT05712083
- Testing
- BCMA CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Chronic Myeloid Leukemia
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.
- Trial name
- NCT01490983
- Testing
- no access to eMedonline, eMedonline access
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Rex Cancer Center, Raleigh, NC
Leukemia, Acute Myeloid Leukemia
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy.
- Conditions
- Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children
- Trial name
- NCT06810583
- Testing
- Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- St. Jude Children's Research Hospital
Sickle Cell Disease
Study of Blood Platelets in Sickle Cell Disease
We are studying if sickle cell disease blood platelets are larger than normal and how they may cause obstruction of blood vessels.
- Trial name
- NCT00226083
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Rockefeller University
Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD)
Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
The purpose of this study is to explore the key symptoms of individuals with systemic mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease symptoms and condition.
- Conditions
- Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD), Mast Cell Leukemia (MCL), Smoldering Systemic Mastocytosis (SSM)
- Trial name
- NCT02380222
- Testing
- Interview
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Adelphi Values LLC
Idiopathic Thrombocytopenic Purpura
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Thrombopoietin Receptor Agonists (TPO-ra) are novel treatment modalities for patients with refractory Primary Immune Thrombocytopenia (ITP), but only few data are available for long-term effects of these drugs.
- Trial name
- NCT01443351
- Where
- Denmark
- Sponsor
- Zealand University Hospital
Sickle Cell Anemia
A Phase II Trial of Regadenoson in Sickle Cell Anemia
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called Regadenoson (or Lexiscan) to learn whether the drug works in treating a specific disease, in this case…
- Trial name
- NCT01788631
- Testing
- Regadenoson
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.